Gilead Sciences Short Interest Ratio and Short Volume

Short interest is the volume of Gilead Sciences shares that have been sold short but have not yet been covered or closed out. As of October 30th, investors have sold 22,700,000 shares of GILD short. 1.82% of Gilead Sciences' shares are currently sold short. View details.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Gilead Sciences currently has a short interest ratio of 2.0.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.82% of Gilead Sciences' floating shares are currently sold short.

Gilead Sciences saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 22,700,000 shares, an increase of 10.7% from the previous total of 20,500,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Gilead Sciences currently has issued a total of 1,253,528,000 shares. Some of Gilead Sciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Gilead Sciences currently has a public float of 1,250,000,000 shares.

1.82% of Gilead Sciences' shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Gilead Sciences: Amgen Inc. (1.22%), Vertex Pharmaceuticals Incorporated (0.00%), Regeneron Pharmaceuticals, Inc. (2.13%), Biogen Inc. (2.47%), Seagen Inc. (0.00%), Alexion Pharmaceuticals, Inc. (1.94%), Incyte Co. (0.00%), Exact Sciences Co. (0.00%), Alnylam Pharmaceuticals, Inc. (0.00%), and BioMarin Pharmaceutical Inc. (0.00%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.66 billion), Aon Plc ($3.83 billion), Analog Devices, Inc. ($3.33 billion), ViacomCBS Inc. ($3.13 billion), Snap Inc. ($3.05 billion), The Clorox Company ($2.85 billion), Uber Technologies, Inc. ($2.80 billion), Moderna, Inc. ($2.26 billion), Simon Property Group, Inc. ($2.02 billion), and International Flavors & Fragrances Inc. ($1.96 billion). View all of the most shorted stocks.

Short selling GILD is an investing strategy that aims to generate trading profit from Gilead Sciences as its price is falling. Gilead Sciences' stock is trading down $0.75 today. To short Gilead Sciences stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Gilead Sciences will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Gilead Sciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GILD, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GILD, twice per month. The most recent reporting period available is October, 30 2020.